Pfizer's stock is down roughly 60% from its late 2021 highs, but the drug giant is working to innovate its way back into the big leagues.

NEW YORK, Aug 13 (Reuters) - Drugmakers Pfizer Inc, BioNTech and Moderna Inc are expected to reap billions of dollars from COVID-19 booster shots in a market that could rival the $6 billion in annual ...

The U.S. surpassed 1 million COVID-19 deaths last week. In the wake of the tragic milestone of 1 million official COVID-19 deaths in the United States, a new analysis found that without vaccines, the ...

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a ...

Four years into a Congressional probe of Big Pharma’s potential abuse of a 2017 tax break, Democratic lawmakers have homed in on Pfizer, accusing the New York drugmaker of some of the most egregious ...

Pfizer (NYSE:PFE) has faced significant challenges in recent years, with the stock losing half its value since late 2021 as COVID-19 vaccine demand waned. The pharmaceutical giant has struggled to ...

Pfizer is a $145 billion pharmaceutical industry giant with a long history of success behind it. Wall Street bid the stock up during the COVID-19 pandemic, but now investors have soured on the shares.

There were 1,399 unusually active options in Thursday’s trading. Pfizer’s March 20 $29 put had the highest Vol/OI ratio at ...

Despite its historical underperformance and declining dividend growth trajectory, Pfizer's 7.63% dividend yield is attractive, making it a compelling income stock candidate. CEO Bourla's strategic ...

Pfizer’s powerhouse drug portfolio in 2015 has since become considerably less impressive. The pharmaceutical giant also arguably invested too many resources in COVID-19 solutions at the expense of ...

Pfizer is deeply undervalued, trading at a multi-year low with a 6.65% dividend yield, making it a compelling long-term opportunity. Recent double-digit earnings growth, strong margins, and cost ...

Both Ford and Pfizer have very attractive dividend yields.